Description: MorphoSys AG engages in the development of therapeutic antibodies to cure inflammatory and autoimmune diseases, as well as cancer and infectious diseases. The company operates through two business segments; Partnered Discovery and Proprietary Development.
Home Page: www.morphosys.com
MOR Technical Analysis
Semmelweisstrasse 7
Planegg,
82152
Germany
Phone:
49 89 89927 0
Officers
| Name | Title |
|---|---|
| Dr. Jean-Paul Kress M.D. | Chairman of Management Board, MD & CEO |
| Mr. Sung H. Lee | CFO & Member of Management Board |
| Dr. Marlies Sproll | Special Adviser to the Chief Exec. Officer |
| Mr. Klaus De Wall | Head of Accounting & Tax |
| Ms. Lara Smith Weber | Head of Controlling, Corp. Fin. & Corp. Devel. |
| Dr. Margit Urban | Head of Discovery Alliances & Technologies |
| Dr. Anja Pomrehn | Sr. VP & Head of Investor Relations |
| Ms. Charlotte Lohmann | Sr. VP of Legal, Compliance & IP and Gen. Counsel |
| Mr. Thomas Biegi | VP & Head of Corp. Communications |
| Ms. Maria Castresana | Sr. VP & Global Head of HR |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 322.5806 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.409 |
| Price-to-Sales TTM: | 2.1842 |
| IPO Date: | 1999-03-09 |
| Fiscal Year End: | December |
| Full Time Employees: | 627 |